Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes

Lapatinib has been used in combination with capecitabine or paclitaxel to treat patients with progressive HER2-overexpressing metastatic breast cancer (MBC). Unfortunately, an increased incidence of hepatotoxicity had been reported in the combinational therapy. The aim of this study was to investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, ChunLing, Ma, ShaoLin, Wang, Fang, Zhao, HongYun, Wu, XingPing, Huang, ZhenCong, Chen, ZheSheng, To, Kenneth, Fu, LiWu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627342/
https://www.ncbi.nlm.nih.gov/pubmed/26036634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627342/
https://www.ncbi.nlm.nih.gov/pubmed/26036634

Ejemplares similares